TY  - JOUR
A1  - Bleilevens, Christian
A1  - Soppert, Josefin
A1  - Hoffmann, Adrian
A1  - Breuer, Thomas
A1  - Bernhagen, Jürgen
A1  - Martin, Lukas
A1  - Stiehler, Lara
A1  - Marx, Gernot
A1  - Dreher, Michael
A1  - Stoppe, Christian
A1  - Simon, Tim-Philipp
T1  - Macrophage migration inhibitory factor (MIF) plasma concentration in critically ill COVID-19 patients: a prospective observational study
JF  - Diagnostics
N2  - Mortality in critically ill coronavirus disease 2019 (COVID-19) patients is high and pharmacological treatment strategies remain limited. Early-stage predictive biomarkers are needed to identify patients with a high risk of severe clinical courses and to stratify treatment strategies. Macrophage migration inhibitory factor (MIF) was previously described as a potential predictor for the outcome of critically ill patients and for acute respiratory distress syndrome (ARDS), a hallmark of severe COVID-19 disease. This prospective observational study evaluates the predictive potential of MIF for the clinical outcome after severe COVID-19 infection. Plasma MIF concentrations were measured in 36 mechanically ventilated COVID-19 patients over three days after intensive care unit (ICU) admission. Increased compared to decreased MIF was significantly associated with aggravated organ function and a significantly lower 28-day survival (sequential organ failure assessment (SOFA) score; 8.2 ± 4.5 to 14.3 ± 3, p = 0.009 vs. 8.9 ± 1.9 to 12 ± 2, p = 0.296; survival: 56% vs. 93%; p = 0.003). Arterial hypertension was the predominant comorbidity in 85% of patients with increasing MIF concentrations (vs. decreasing MIF: 39%; p = 0.015). Without reaching significance, more patients with decreasing MIF were able to improve their ARDS status (p = 0.142). The identified association between an early MIF response, aggravation of organ function and 28-day survival may open future perspectives for biomarker-based diagnostic approaches for ICU management of COVID-19 patients.
KW  - Macrophage Migration Inhibitory Factor (MIF)
KW  - COVID-19
KW  - ICU treatment
KW  - acute respiratory distress syndrome (ARDS)
KW  - SOFA Score
KW  - Horowitz Quotient
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228967
SN  - 2075-4418
VL  - 11
IS  - 2
ER  -